• RoActemra, IL-1 Inhibitors Better Than Enbrel to Manage JA, Study Suggests
  • Frequency of Remission in Juvenile Idiopathic Arthritis Rises with Disease Duration, Review Study Shows
  • Older Age, Disability, Longer Disease Duration Are Risk Factors for Greater Pain in JIA Patients
  • JIA Increases Risk of Pregnancy Complications, Swedish Study Suggests
  • Biosimiliar Erelzi Now Available in 2 Canadian Provinces for Arthritis, Other Inflammatory Conditions
  • Amgen Launches Enbrel Mini Single-dose Prefilled Cartridge with Reusable Autoinjector
  • US Phase 3 Trial Evaluating Efficacy of Sobis’ Kineret Gets Underway
  • Humira Biosimilar Cyltezo Approved in Europe to Treat Chronic Inflammatory Diseases
  • Teens with Juvenile Arthritis Find Help in Online Educational Program
  • Momenta and Mylan’s Biosimilar Candidate M834 Misses Initial Trial Goals
  • Higher Rate of Infections in JIA Patients Who Take Biologic Therapies, Study Finds
  • Physical Activity in JIA Patients Deteriorates with Time, Long-term Study Finds